Mga Batayang Estadistika
| LEI | 5493003LCY77N7FXK844 |
| CIK | 1484565 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Soleno Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 18, 2025 |
EX-99.1 Corporate Presentation August 2025 | Soleno Therapeutics Exhibit 99.1 | © 2025 Soleno Therapeutics Certain Notices and Disclaimers Forward-Looking Statements This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentio |
|
| August 6, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., August 6, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| July 11, 2025 |
SOLENO THERAPEUTICS ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 SOLENO THERAPEUTICS ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 |
|
| July 11, 2025 |
424B5 1 d23450d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) 2,352,941 Shares Common Stock We are offering 2,352,941 shares of our common stock, par value $0.001 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “SLNO.” The last reported sale price of our c |
|
| July 11, 2025 |
SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in |
|
| July 11, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 SOLENO THERAPEUTICS INC Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| July 11, 2025 |
EX-1.1 2 d52794dex11.htm EX-1.1 Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. Shares of Common Stock Underwriting Agreement July 10, 2025 Goldman Sachs & Co. LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Guggenheim Securities, LLC 33 |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 10, 2025 |
EX-99.1 Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PRELIMINARY FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) - Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and o |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 10, 2025 |
SUBJECT TO COMPLETION, DATED JULY 10, 2025 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| May 7, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results REDWOOD CITY, Calif., May 7, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial r |
|
| April 22, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 18, 2025 |
Letter from Marcum LLP dated April 18, 2025 Exhibit 16.1 April 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Soleno Therapeutics, Inc. under Item 4.01 of its Form 8-K dated April 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Soleno Therapeutics, Inc. co |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 26, 2025 |
Exhibit 99.1 Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 – Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company dev |
|
| February 28, 2025 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| February 28, 2025 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.17 SOLENO THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As most recently amended and restated on February 25, 2025) Soleno Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain, and reward Dir |
|
| February 28, 2025 |
Exhibit 19.1 SOLENO THERAPEUTICS, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (As amended on November 9, 2024) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 1 Compliance Officer 2 Reporting violations 2 Pers |
|
| February 28, 2025 |
Employment Agreement by and between the Company and Meredith Manning, dated January 23, 2024 Exhibit 10.12 SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of January 23, 2024, (the “Effective Date”) by and between Soleno Therapeutics, Inc. (the “Company”), and Meredith Manning (“Executive”). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement between the Executive |
|
| February 28, 2025 |
Employment Agreement by and between the Company and Patricia Hirano, dated January 1, 2019 Exhibit 10.10 SOLENO THERAPEUTICS, INC. (FKA CAPNIA, INC.) EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is entered into effective as of January 1, 2019, (the "Effective Date") by and between Soleno Therapeutics, Inc. (FKA Capnia, Inc.) (the "Company"), and Patricia C. Hirano ("Executive"). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement be |
|
| February 28, 2025 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics U.K. Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Exhibit 10.16 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreeme |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| February 27, 2025 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif., February 27, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter a |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 21, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| December 17, 2024 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2024 |
Exhibit 99.1 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Up to $200 million financing, includes $50 million upfront REDWOOD CITY, Calif., December 17, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 26, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| November 26, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome PDUFA target action date extended by three months to March 27, 2025 REDWOOD CITY, Calif., November 26, 2024 – Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tre |
|
| November 19, 2024 |
SLNO / Soleno Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d790258dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| November 14, 2024 |
SLNO / Soleno Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d868392dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| November 14, 2024 |
SC 13G 1 p24-3169sc13g.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-1 2 p24-3169exhibit1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addition |
|
| November 12, 2024 |
SLNO / Soleno Therapeutics, Inc. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3040sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*, ** Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropr |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| November 6, 2024 |
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results REDWOOD CITY, Calif., November 6, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter end |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| October 21, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A 1 d890003dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 |
|
| October 15, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 |
|
| October 10, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 |
|
| September 10, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washingt |
|
| September 5, 2024 |
SC 13G 1 ea0213665-13gvivosoleno.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) August 27, 2024 (Date of Event Which Requires Filing of this Stat |
|
| September 5, 2024 |
EX-99.1 2 ea021366501ex99-1soleno.htm JOINT FILING STATEMENT Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fili |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| August 15, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces Updates to its Board of Directors Ernest Mario, Ph.D. steps down as Chair for health reasons; Matthew Pauls, J.D., M.B.A. assumes role of Lead Independent Director Dawn Carter Bir, seasoned biotech executive with significant commercial and strategic expertise, joins the Board of Directors REDWOOD CITY, Calif., August 15, 2024 – Soleno Therapeutics, Inc. ( |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. |
|
| August 7, 2024 |
Lease agreement between the Company and 1 Twin Property Owner, LLC dated June 13, 2024 Exhibit 10.1 SHORES CENTER OFFICE LEASE This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between 1 Twin Property Owner LLC, a Delaware limited liability company ("Landlord") and Soleno Therapeutics, Inc., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE D |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| August 7, 2024 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results REDWOOD CITY, Calif., August 7, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second qua |
|
| August 7, 2024 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| July 19, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM July 19, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 19, 2024 |
Up to $150,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) Up to $150,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In acco |
|
| July 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Soleno Therapeutics, Inc. |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 19, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif., June 28, 2024 – Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today ann |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2024 |
Amended and Restated 2014 Equity Incentive Plan and forms of agreement thereunder Exhibit 10.1 AMENDED AND RESTATED SOLENO THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN (Effective as of June 6, 2024) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s busines |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 9, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended Ma |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| May 7, 2024 |
Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT May 2, 2024 PIPER SANDLER & CO. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule I attached hereto c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2024 |
SOLENO THERAPEUTICS ANNOUNCES PRICING OF APPROXIMATELY $138 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PRICING OF APPROXIMATELY $138 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., May 2, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public |
|
| May 6, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) 3,000,000 Shares of Common Stock We are offering 3,000,0000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “SLNO.” On May 1, 2024, the last reported sale price of shares of our co |
|
| May 2, 2024 |
Subject to completion, dated May 2, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| May 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Kevin Dai Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address and Telephone Number o |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| April 29, 2024 |
Exhibit 99.1 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 RE |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 7, 2024 |
Outside Director Compensation Policy Exhibit 10.59 SOLENO THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Adopted on March 5, 2024) Soleno Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain, and reward Directors who are not employees of th |
|
| March 7, 2024 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics U.K. Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| March 7, 2024 |
Exhibit 10.58 LICENSE AGREEMENT FOR SPACE AND SERVICES THIS LICENSE AGREEMENT FOR SPACE AND SERVICES (known as the “Agreement” or the “License”) is made and entered into as of the 8th day of February , 2024, by and among HUDSON TOWERS AT SHORE CENTER, LLC, a Delaware limited liability company, as licensor (“Licensor”) and SOLENO THERAPEUTICS, INC., a Delaware corporation, as licensee (“Licensee”). |
|
| March 7, 2024 |
Exhibit 97.1 SOLENO THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY As adopted October 18, 2023 Soleno Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-f |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2024 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results REDWOOD CITY, Calif., March 6, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourt |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| February 14, 2024 |
US8342033094 / SOLENO THERAPEUTICS INC / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
SLNO / Soleno Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SOLENO THERAPEUTICS, INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 7, 2024 |
SC 13G/A 1 p24-0474sc13ga.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Stateme |
|
| January 31, 2024 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| January 30, 2024 |
2020 Inducement Equity Incentive Plan, as amended on January 24, 2024 Exhibit 10.1 SOLENO THERAPEUTICS, INC. 2020 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonsta |
|
| January 17, 2024 |
As filed with the Securities and Exchange Commission on January 17, 2024 S-8 As filed with the Securities and Exchange Commission on January 17, 2024 Registration No. |
|
| January 17, 2024 |
Calculation of Filing Fees Table EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 4, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| January 2, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Soleno Therapeutics, Inc. |
|
| January 2, 2024 |
EX-4.3 Exhibit 4.3 SOLENO THERAPEUTICS, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 6 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establish |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| November 8, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| October 27, 2023 |
October 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Soleno Therapeutics, Inc. Registration Statement on Form S-3 File No. 333- 275120 Acceleration Request Requested Date: October 31, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under th |
|
| October 23, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| October 20, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) SOLENO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amo\unt of Registration Fee Fees to be Paid Equity Common |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 20, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 20, 2023 Registration No. |
|
| October 16, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| October 12, 2023 |
SC 13G 1 p23-2583sc13g.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of This Statement) Chec |
|
| October 12, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / COMMODORE CAPITAL LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| October 11, 2023 |
SC 13D/A 1 ea186624-13da1vivosoleno.htm AMENDMENT NO. 1 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Hongbo Lu Vivo Capital LLC 192 Lytton Avenue Palo Alto, |
|
| October 10, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 834203309 (CUSIP Number) September 28, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| October 5, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) September 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| October 3, 2023 |
EX-99.4 2 d533581dex994.htm EX-99.4 Exhibit 99.4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Fred |
|
| October 3, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| September 29, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants September 28, 2023 REDWOOD CITY, Calif., September 28, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company develo |
|
| September 29, 2023 |
Exhibit 1.2 Execution Version 1,825,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,175,000 Shares of Common Stock Soleno Therapeutics, Inc. PLACEMENT AGENCY AGREEMENT September 28, 2023 Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, New York 10022 Oppenheimer & Co. Inc. 85 Broad Street New York, |
|
| September 29, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d498788dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 28, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| September 29, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, on the terms and subject to t |
|
| September 29, 2023 |
3,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 9, 2021) 3,000,000 Shares of Common Stock We are offering 3,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “SLNO.” On September 27, 2023, the last reported sale price of shares of |
|
| September 29, 2023 |
Exhibit 10.2 NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWI |
|
| September 29, 2023 |
Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT September 28, 2023 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Soleno Therapeutics, Inc., a corporation organized and existing |
|
| September 28, 2023 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated September 28, 2023 Relating to Preliminary Prospectus Supplement Dated September 27, 2023 Registration Statement Nos. |
|
| September 28, 2023 |
FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated September 28, 2023 Relating to Preliminary Prospectus Supplement Dated September 27, 2023 Registration Statement Nos. |
|
| September 27, 2023 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 27, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the acco |
|
| September 27, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) SOLENO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| September 27, 2023 |
As filed with the Securities and Exchange Commission on September 27, 2023 As filed with the Securities and Exchange Commission on September 27, 2023 Registration No. |
|
| September 26, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| August 30, 2023 |
SLNO / Soleno Therapeutics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC (Name of Issuer) Common Shares (Title of Class of Securities) 834203200 (CUSIP Number) June 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| August 18, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 15, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 16, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors REDWOOD CITY, Calif., August 16, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board |
|
| August 15, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| August 8, 2023 |
FIRST AMENDMENT THIS FIRST AMENDMENT (this “Amendment”) is made and entered into as of April 24 , 2023, by and between HUDSON TOWERS AT SHORE CENTER, LLC, a Delaware limited liability company (“Landlord”), and SOLENO THERAPEUTICS, INC. |
|
| August 8, 2023 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results REDWOOD CITY, Calif., August 8, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the second quarter ende |
|
| August 8, 2023 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| August 8, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2023 |
July 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Soleno Therapeutics, Inc. Registration Statement on Form S-1 File No. 333- 273373 Acceleration Request Requested Date: August 2, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 28, 2023 Registration No. |
|
| July 21, 2023 |
Power of Attorney (included on the signature page to this Registration Statement) S-1 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2023 Registration No. |
|
| July 21, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Soleno Therapeutics, Inc. |
|
| July 10, 2023 |
EX-99.1 Exhibit 99.1 Corporate Presentation July 2023 | Soleno Therapeutics Certain Notices and Disclaimers Forward-Looking Statements This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlo |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| June 2, 2023 |
Up to $8,878,028 of Shares Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 AMENDMENT NO. 2 DATED JUNE 2, 2023 to Prospectus Supplement dated July 16, 2021 (To Prospectus dated February 9, 2021) Up to $8,878,028 of Shares Common Stock This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated July 16, 2021 (the “Prospectus Supplement”). This Amendment should be |
|
| June 1, 2023 |
Joint Filing Agreement (filed herewith). Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be r |
|
| June 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Frank Kung Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address and Telephone Number o |
|
| May 30, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 26, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 25, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d444551dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| May 18, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telep |
|
| May 18, 2023 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: May 18, 2023 PERCEPT |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203200 (CUSIP Number) May 8, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 15, 2023 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| May 10, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| May 9, 2023 |
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results REDWOOD CITY, Calif., May 9, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter e |
|
| May 9, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 3, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 3, 2023 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome Enrollment completion satisfies closing condition on December 2022 Securities Purchase Agreement and triggers $10 million capital infusion |
|
| April 14, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 4, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 23, 2023 |
As filed with the Securities and Exchange Commission on March 23, 2023 S-8 As filed with the Securities and Exchange Commission on March 23, 2023 Registration No. |
|
| March 23, 2023 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| March 22, 2023 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics UK Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| March 21, 2023 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial Results REDWOOD CITY, Calif., March 21, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for |
|
| March 21, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 21, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| February 24, 2023 |
2020 Inducement Equity Incentive Plan, as amended, and form of option agreement thereunuder EX-10.1 Exhibit 10.1 SOLENO THERAPEUTICS, INC. 2020 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant o |
|
| February 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 17, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| February 15, 2023 |
SLNO / Soleno Therapeutics Inc / HIRSCHMAN ORIN Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC (Name of Issuer) Common Shares (Title of Class of Securities) 834203200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2023 |
SLNO / Soleno Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm236168d32sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203200 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check th |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 25, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| December 20, 2022 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Add |
|
| December 19, 2022 |
Form of Tranche B Warrant to Purchase Common Stock EX-10.3 Exhibit 10.3 [FORM OF TRANCHE B WARRANT] SOLENO THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS Warrant No.: Number of Shares of Common Stock or Exchange Warrants: Date of Issuance: [], 2023 (“Issuance Date”) Soleno Therapeutics, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable consideration, the rec |
|
| December 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 16, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| December 19, 2022 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Financing Commitment for up to $60 Million Funding from Three Leading Healthcare Investors, with Vivo Capital Joining Existing Investors Nantahala Capital and Abingworth $10 million capital infusion at closing and $15 million upon positive data to support NDA filing Additional $35 million capital upon FDA approval to enable commercialization REDWO |
|
| December 19, 2022 |
Securities Purchase Agreement dated December 16, 2022 EX-10.1 Exhibit 10.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 16, 2022, between Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, on t |
|
| December 19, 2022 |
Form of Tranche A Warrant to Purchase Common Stock EX-10.2 Exhibit 10.2 [FORM OF TRANCHE A WARRANT] SOLENO THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK OR EXCHANGE WARRANTS Warrant No.: Number of Shares of Common Stock or Exchange Warrants: (the “Total Amount”) Date of Issuance: [], 2023 (“Issuance Date”) Soleno Therapeutics, Inc., a company organized under the laws of Delaware (the “Company”), hereby certifies that, for good and valuable c |
|
| November 9, 2022 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| November 9, 2022 |
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results REDWOOD CITY, Calif., November 9, 2022 ? Soleno Therapeutics, Inc. (?Soleno?) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine |
|
| November 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 9, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| October 3, 2022 |
Exhibit 99.1 Soleno Therapeutics Announces Initiation of Randomized Withdrawal Study of DCCR for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif., October 3, 2022 ? Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has initiated a randomize |
|
| October 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 3, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 25, 2022 |
Certificate of Amendment to the Certificate of Incorporation Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SOLENO THERAPEUTICS, INC. Soleno Therapeutics, Inc., a Delaware corporation (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Soleno Therapeutics, Inc. The Corporation?s original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on |
|
| August 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 24, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 11, 2022 |
EX-99.4 Exhibit 4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Frederick, Kevin Gasque, Erica Herb |
|
| August 11, 2022 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13D. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning su |
|
| August 11, 2022 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 (Name, Add |
|
| August 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| August 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 10, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 10, 2022 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results REDWOOD CITY, Calif., August 10, 2022 ? Soleno Therapeutics, Inc. (?Soleno?) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six m |
|
| July 25, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| July 20, 2022 |
Exhibit 99.1 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome FDA acknowledges that data from a randomized withdrawal period of Study C602 have the potential to support an NDA submission REDWOOD CITY, Calif., July 20, 2022 ? Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel |
|
| July 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 20, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 10, 2022 |
Up to $7,682,909 of Shares Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 AMENDMENT NO. 1 DATED JUNE 10, 2022 to Prospectus Supplement dated July 16, 2021 (To Prospectus dated February 9, 2021) Up to $7,682,909 of Shares Common Stock This Amendment No. 1 to Prospectus Supplement (this ?Amendment?) amends our prospectus supplement dated July 16, 2021 (the ?Prospectus Supplement?). This Amendment should be read |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 10, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| May 10, 2022 |
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial Results REDWOOD CITY, Calif., May 10, 2022 ? Soleno Therapeutics, Inc. (?Soleno?) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three months ended |
|
| April 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 21, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 8, 2022 |
SLNO / Soleno Therapeutics Inc / Abingworth LLP - AMENDMENT NO. 2 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Soleno Therapeutics Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) John Heard Abingworth LLP Princes House 38 Jermyn Street London, England SW1Y 6DN +44 20 7534 1500 (Name, Address an |
|
| April 5, 2022 |
SLNO / Soleno Therapeutics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC (Name of Issuer) Common Shares (Title of Class of Securities) 834203200 (CUSIP Number) March 29, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed ☐ |
|
| April 5, 2022 |
EXHIBIT 1 JOINT FILING AGREEMENT The undersigned hereby agree that the statement on Schedule 13D with respect to the Common Stock of Soleno Therapeutics, Inc. |
|
| April 5, 2022 |
SLNO / Soleno Therapeutics Inc / Jack W. Schuler Living Trust - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 834203200 (CUSIP Number) Jack W. Schuler 100 N. Field Drive, Suite 360 Lake Forest, Illinois 60045 (224)-880-1210 (Name, Address and Teleph |
|
| March 31, 2022 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics UK Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| March 31, 2022 |
As filed with the Securities and Exchange Commission on March 31, 2022 As filed with the Securities and Exchange Commission on March 31, 2022 Registration No. |
|
| March 31, 2022 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| March 30, 2022 |
Form of Common Warrant To Purchase Common Stock. Exhibit 4.2 [FORM OF WARRANT] SOLENO THERAPEUTICS, INC. WARRANT TO PURCHASE COMMON STOCK Warrant No.: Number of Shares of Common Stock: Date of Issuance: [], 2022 (?Issuance Date?) Soleno Therapeutics, Inc., a company organized under the laws of Delaware (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [HOLDE |
|
| March 30, 2022 |
Exhibit 1.1 40,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase 20,000,000 Shares of Common Stock Warrants to Purchase 60,000,000 Shares of Common Stock Soleno Therapeutics, Inc. UNDERWRITING AGREEMENT March 28, 2022 Oppenheimer & Co. Inc. as Representative of the several Underwriters named in Schedule I hereto 85 Broad Street New York, NY 10004 Ladies and Gentlemen: Soleno Therapeut |
|
| March 30, 2022 |
Exhibit 99.1 Soleno Therapeutics Announces Pricing of Approximately $15 Million Underwritten Public Offering REDWOOD CITY, Calif., March 29, 2022 (GLOBE NEWSWIRE) ? Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the pricing of an underwritten public offering of 40,000,00 |
|
| March 30, 2022 |
Form of Pre-Funded Warrant To Purchase Common Stock. Exhibit 4.1 PREFUNDED COMMON STOCK PURCHASE WARRANT SOLENO THERAPEUTICS, INC. Warrant Shares: [XX] Initial Exercise Date: March [DD], 2022 THIS PREFUNDED COMMON STOCK PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, [PURCHASER] or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any ti |
|
| March 30, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 28, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 30, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 9, 2021) 40,000,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 20,000,000 Shares of Common Stock Warrants to Purchase up to 60,000,000 Shares of Common Stock We are offering 40,000,000 shares of our common stock, par value $0.001 per share, and accomp |
|
| March 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 28, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 28, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| March 28, 2022 |
Soleno Therapeutics Announces Proposed Underwritten Public Offering Exhibit 99.1 Soleno Therapeutics Announces Proposed Underwritten Public Offering REDWOOD CITY, Calif., March 28, 2022 (GLOBE NEWSWIRE) ? Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public |
|
| March 18, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 16, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| February 14, 2022 |
SLNO / Soleno Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203200 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu |
|
| February 11, 2022 |
SLNO / Soleno Therapeutics Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 28, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| January 24, 2022 |
Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome Exhibit 99.1 Soleno Therapeutics Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif., January 24, 2022 ? Soleno Therapeutics, Inc. (Soleno or the Company) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update following recent interactions with the U.S. Food |
|
| January 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2022 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| December 30, 2021 |
Exhibit 10.1 ASSIGNMENT AGREEMENT This ASSIGNMENT AGREEMENT (this ?Agreement?) is effective as of December 28, 2021 (the ?Effective Date?), by and among Soleno Therapeutics, Inc., a Delaware corporation, f/k/a Capnia, Inc. (the ?Company?), and Vivo Ventures Fund V, L.P. and Vivo Ventures V Affiliates Fund, L.P. (collectively, ?Vivo?). Background A. Reference is made to the Agreement and Plan of Me |
|
| December 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 28, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2021 |
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2021 Financial Results REDWOOD CITY, Calif., November 10, 2021 ? Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and nine m |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| September 17, 2021 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| July 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 28, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| July 28, 2021 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results REDWOOD CITY, Calif., July 28, 2021 ? Soleno Therapeutics, Inc. (?Soleno?) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the three and six mon |
|
| July 16, 2021 |
Exhibit 1.1 Execution Version Soleno Therapeutics, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement July 16, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: Soleno Therapeutics, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with Cantor Fitzgerald & Co. (the ?Agent?), |
|
| July 16, 2021 |
Up to $25,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 9, 2021) Up to $25,000,000 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald & Co., or Cantor Fitzgerald, relating to shares of our common stock, $0.001 par value per share, offered by this |
|
| July 16, 2021 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 16, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 12, 2021 |
SLNO / Soleno Therapeutics Inc / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203200 (CUSIP Number) June 30, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursua |
|
| June 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| June 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 1, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 5, 2021 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
